Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

A New Post Hoc Analysis Indicates asenapine has Effect on Both Manic and Depressive Symptoms in Bipolar I Disorder Patients Experiencing Mixed Episodes


News provided by

Lundbeck

15 Oct, 2012, 11:30 GMT

Share this article

Share toX

Share this article

Share toX

ECNP, VIENNA, October 15, 2012 /PRNewswire/ --

Post hoc analyses presented at the 25th European College of Neuropsychopharmacology (ECNP) congress show asenapine achieves significant control of mixed episodes in bipolar I disorder compared to placebo.

- For media outside China, Japan, UK, USA only.

Lundbeck today announced results from post hoc analyses in bipolar I disorder patients experiencing mixed episodes, which found asenapine has a significant effect on both manic and depressive symptoms versus placebo. The analyses used pooled data from two identically designed 3-week, randomised, double-blind flexible dose, placebo- and olanzapine-controlled trials and a 9-week, double-blind olanzapine-controlled extension study.

"One of the most challenging treatment goals in bipolar I disorder is to address mixed episodes, where both manic and depressive symptoms are present," said Professor Jean-Michel Azorin, Professor of Psychiatry at the Mediterranean University School of Medicine. "Mixed episodes are experienced by more than 40% of patients and are considered a severe presentation of bipolar I disorder. Further investigation into the potential to manage both depressive and manic symptoms simultaneously with one treatment is warranted."

Asenapine is a tetracyclic antipsychotic therapy for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults. The efficacy of asenapine was studied using two scales; for manic symptoms the Young Mania Rating Scale (YMRS) and the Montgomery- Åsberg Depression Rating Scale (MADRS) for depressive symptoms.[1]

The changes in YMRS score from baseline to week 3 were:

  • Significantly greater with asenapine (-15.0 ± 0.9) compared to placebo (-11.5 ± 1.2; p=0.015)
  • The difference between olanzapine and placebo was not statistically significant
    (-13.3 ± 0.9; p=0.169)

Asenapine was also significantly superior to placebo in change from baseline in MADRS total score at week 3 (-8.2 ± 0.9 versus -4.5 ± 1.2, respectively; p=0.009). The difference between olanzapine and placebo was not statistically significant (-6.5 ± 0.8; p=0.181).[2]

The composite response of both manic and depressive measures (classified as ≥ 50% reduction in YMRS and MADRS scores) rate at week 3 was:

  • Significantly greater with asenapine (46.3%) than with placebo (24.4%; p=0.023)
  • The difference between olanzapine and placebo was not statistically significant (37.5%; p=0.141)

The composite remission (YMRS ≤ 12 and MADRS ≤ 10) rate was significantly greater with asenapine (44.8%) than placebo (24.4%; p=0.033) at week 3; the difference with olanzapine was not significant (35.2%; p=0.218).[2]

Bipolar disorder affects 30 million people worldwide including over four million people in Europe.[2] It is the sixth leading cause of disability worldwide.[3] People with bipolar disorder are part of a medically-burdened population that often experience multiple complications. It is estimated that approximately two thirds of patients will suffer a mixed episode at some point in their illness.[4]

Editor notesAbout the post hoc analyses

The efficacy of asenapine in the treatment of mixed episodes was assessed using post hoc analyses on pooled data from two identically designed 3-week, randomised, double blind, flexible dose, placebo- and olanzapine-controlled trials and a 9-week, double-blind olanzapine-controlled extension study.[2]

In the intent-to-treat population, 295 patients has a DSM-IV-TR mixed episode (placebo: 66; olanzapine: 122; asenapine: 107) in the 3-weeks trials. Of these, 102 patients (olanzapine: 56; asenapine: 46) entered the 9-week extension study.[2]

These post hoc analyses were conducted on the pooled 3-week data of the subset of patients diagnosed with a mixed episode according to DSM-IV-TR, and complemented by the data collected during the 9-week extension trial.[2]

About bipolar I disorder

Bipolar disorder (also known as manic-depressive disorder) is a chronic, episodic illness so named because sufferers alternate between two poles of extreme moods - mania and depression.[5] Bipolar I disorder is characterised by mania (episodes of elevated moods, extreme irritability, decreased sleep and increased energy), depression (overwhelming feelings of sadness, suicidal thoughts), or a combination of both.[5]

About asenapine

Asenapine is a sublingual tablet indicated for the treatment of moderate to severe manic episodes of bipolar I disorder in adults.  Approximately 4,500 subjects, including more than 3,150 patients in phase II/III studies (including trials in schizophrenia), have contributed to asenapine safety and tolerability data and the clinical trial programme for asenapine has included nearly 1,300 patients with manic or mixed episodes of bipolar I disorder.[6],[7],[8]

About Lundbeck

H. Lundbeck A/S (LUN.CO, LUN DC, HLUKY) is an international pharmaceutical company highly committed to improving the quality of life for people suffering from brain disorders. For this purpose, Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The company's products are targeted at disorders such as depression and anxiety, psychotic disorders, epilepsy and Huntington's, Alzheimer's and Parkinson's diseases.

Lundbeck was founded in 1915 by Hans Lundbeck in Copenhagen, Denmark. Today Lundbeck employs approximately 6,000 people worldwide. Lundbeck is one of the world's leading pharmaceutical companies working with brain disorders. In 2011, the company's revenue was DKK 16.0 billion (approximately EUR 2.2 billion or USD 3.0 billion). For more information, please visit http://www.lundbeck.com/.

References

1. Azorin, et al. Remission of Manic and Depressive Symptoms with Asenapine in Patients with Mixed Episodes. Presented at the 25th European College of Neuropsychopharmacology (ECNP) Congress, Vienna, October 2012, Poster 2.e.019

2. World Health Organization. Disease incidence, prevalence and disability. Available at: http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_part3.pdf. Accessed August 24, 2012.

3. Kleinman, L et al. Costs of bipolar disorder. Pharmacoeconomics. 2003;21:601-622.

4. Mackin, P. & Young, A.H. (2005) Bipolar disorders. Core Psychiatry (eds P. Wright, J. Stern, M. Phelan). Edinburgh. Elsevier Saunders.

5. National Institute of Mental Health. Bipolar Disorder 2009. Available at: http://www.nimh.nih.gov/health/publications/bipolar-disorder/nimh-bipolar-adults.pdf. Accessed August 24, 2012.

6. Asenapine Summary of Product Characteristics, 2012.

7. McIntyre, R et al. A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disorders. 2009:11:673-686.

8. McIntyre, R et al. Treatment of Mania in Bipolar I Disorder: Placebo and Olanzapine Controlled trials of Asenapine. Congress of European College of Neuropsychopharmacology, October 13-17, 2007, Vienna, Austria.

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.